cancer vaccine development

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company headquartered in San Jose, California, developing immune-based therapies to treat and prevent cancer. It has two clinical programs: an FSHR-targeted CAR-T therapy (lira-cel) for ovarian cancer in Phase 1 dose escalation, and an alpha-lactalbumin-targeted breast cancer vaccine that has completed Phase 1 and is preparing for Phase 2. Programs are developed with institutions including Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, the National Cancer Institute,

Read more

CAR-T cell therapyclinical stage drug development